IGF2BP3 and neoplasm: We found DD LPS uniquely portended poor survival for IGF2BP3+ tumors (mOS 5.00 vs. 1.6 years, p = 0.0088) (Figure 1B), whereas the remaining tumor subtypes showed no difference in survival (Figure S1A–C).